Which treatment effect is more stable, cabozantinib or anlotinib?

Cabozantinib (Cabozantinib) and anlotinib (Anlotinib) are both multi-target tyrosine kinase inhibitors and are widely used in the treatment of various solid tumors. Cabozantinib mainly inhibits MET, VEGFR, AXL and other kinases, exerting anti-angiogenesis and inhibiting tumor cell proliferation. Anlotinib targets multiple signaling pathways such as VEGFR, FGFR, and PDGFR, which not only inhibits tumor neovascularization but also blocks the growth signals of tumor cells. The mechanisms of the two are similar but their targets are different, which affects their efficacy in different tumors.

Cabozantinib has shown relatively stable and durable efficacy in various cancers such as renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Especially in advanced patients, it can significantly extend progression-free survival and overall survival. Anlotinib has excellent performance in lung cancer, soft tissue sarcoma and thyroid cancer, especially in some patients who have failed chemotherapy, and the maintenance treatment effect is relatively stable. Overall, cabozantinib has accumulated abundant efficacy data, and its stability and sustainability have been verified by multiple large-scale international clinical trials.

The therapeutic effect of the two drugs is also affected by individual patient differences, tumor type and molecular characteristics. Cabozantinib is suitable for a variety of tumors and has inhibitory effects on multiple kinases, with wider indications; anlotinib has outstanding performance in the Chinese market, has mild side effects and is well tolerated, and is suitable for some patients who cannot tolerate the side effects of cabozantinib. In actual clinical practice, doctors will choose more appropriate drugs based on the patient's specific condition, previous treatment history, and tolerance.

Overall, cabozantinib has shown a more durable and reliable therapeutic effect in the treatment of various cancers with its wider clinical application and stable efficacy data. Anlotinib has become an effective choice for many patients due to its good tolerability and certain efficacy stability. Choosing which drug is more stable requires comprehensive consideration of the patient's condition, tumor type and side effect tolerance. It is recommended that patients develop reasonable treatment plans based on individual needs under the guidance of professional doctors to achieve the best efficacy and quality of life.

Reference materials:https://www.drugs.com/